Dr Reddy's Lab rises on launching of Zenatane in US
The total value of the drug sales in the US was approximately $309 million for the 12 month-ending January 2013, according to IMS Health.
Dr Reddy’s Laboratories is trading higher by 2% at Rs 1,802 after the company said it has launched Zenatane in 20 mg and 40 mg in the US following its approval by the United States Food & Drug Administration (USFDA).
“The total value of the drug sales in the US was approximately $309 million for the 12 month-ending January 2013, according to IMS Health,” Dr Reddy’s said in a statement.
Zenatane capsules will be available in boxes of 30 (three prescription packs of 10 capsules), it added.
Zenatane, used for the treatment of acne, is a therapeutically-equivalent generic version of Accutane (Isotretinoin capsules USP) in the US market.
The stock opened at Rs 1,779 and touched high of Rs 1,810 on NSE. A combined 122,787 shares have changed hands on the counter till 1034 hours on NSE and BSE.
“The total value of the drug sales in the US was approximately $309 million for the 12 month-ending January 2013, according to IMS Health,” Dr Reddy’s said in a statement.
Zenatane capsules will be available in boxes of 30 (three prescription packs of 10 capsules), it added.
Zenatane, used for the treatment of acne, is a therapeutically-equivalent generic version of Accutane (Isotretinoin capsules USP) in the US market.
The stock opened at Rs 1,779 and touched high of Rs 1,810 on NSE. A combined 122,787 shares have changed hands on the counter till 1034 hours on NSE and BSE.